https://sciex.com/content/SCIEX/na/us/en


Using wastewater monitoring to assess exposure to PFAS

Jun 9, 2022 | Agriculture, Blogs, Environmental / Industrial, Industrial, Other | 0 comments

Read Time: 3 minutes

Per-and polyfluorinated alkyl substances (PFAS) are known for their water- and grease-resistant properties, which make them useful in many everyday items. In fact, a study from 2020 estimated over 200 “use categories” covering more than 1,400 individual PFAS compounds in commercial products1—they are truly all around us. Due to their extensive presence and potentially harmful effects (these effects are still mostly uncertain), exposure to PFAS is a growing concern. Humans and wildlife have been exposed to these chemicals through a variety of routes, including food packaging, drinking water and cleaning products.2

The potential health risks of PFAS chemicals stem from a combination of “exposure” and inherent “toxicity,” so it is essential to properly identify and quantify PFAS exposure. So, how do we monitor exposure to contaminants such as PFAS?

Monitoring human exposure to contaminants

When individuals are exposed to PFAS, the PFAS accumulate in protein-rich tissues such as blood, liver and kidneys. For this reason, biological examination of PFAS exposure is often conducted using blood matrices. However, many of the approaches used for this type of examination are difficult to conduct when looking at exposures across a population.3 For example, obtaining a statistically significant sample size in a moderately sized city or country requires a lot of human samples. These large studies can be difficult to coordinate, not to mention the difficulties involved with handling human samples.

Another option is using environmental matrices to monitor exposure. Wastewater, for instance, can serve as a powerful tool for assessing the chemical use or consumption patterns of a population over time.4 For many years, wastewater has been used to monitor contaminants such as personal care products and pharmaceuticals (PPCPs) and illegal drugs, and it can also play an important role with PFAS.

Understanding the fate of PFAS through water treatment plants (WTPs) and wastewater treatment plants (WWTPs) can benefit society in addressing PFAS issues.5 While WTPs and WWTPs can remove some contaminants, these plants are not designed to break down persistent organic pollutants such as PFAS, which means that they are detected in the final effluent. This, of course, has implications for aquatic toxicity in the receiving sources, but it can also inform us about PFAS exposure trends within the community.

Analyzing PFAS trends using wastewater

In a recent study from the Queensland Alliance for Environmental Health Sciences and its collaborators, scientists accessed a 10-year wastewater archiving program to conduct a temporal analysis of PFAS trends in an urban Australian population between the years 2010 and 2020. Although the results showed a decline in concentrations for most PFAS, the study also observed a shift in the types of PFAS compounds detected. Specifically, the researchers measured greater proportions of shorter chain-length PFAS as well as replacement compounds.4 These results imply significant shifts in community exposure to PFAS—both the magnitude of exposure and the specific compounds that people were exposed to—which has an impact on the potential human health risk.

Observing these historical trends would have been extremely difficult using traditional exposure techniques such as measuring PFAS serum levels. This study is a useful example of how creative approaches and mass spectrometry can improve our understanding of the human health risk of PFAS.

 

References

  1. Glüge, J. et al. An overview of the uses of per- and polyfluoroalkyl substances (PFAS). Environmental Science: Processes & Impacts, 2020, 22, 2345-2373. https://pubs.rsc.org/en/content/articlelanding/2020/EM/D0EM00291G
  2. DeLuca, N.M. et al. Human exposure pathways to poly- and perfluoroalkyl substances (PFAS) from indoor media: A systematic review. Environment International, Volume 162, 2022, 107149. https://www.sciencedirect.com/science/article/pii/S0160412022000757
  3. Da Silva, B.F. et al. A rapid and simple method to quantify per- and polyfluoroalkyl substances (PFAS) in plasma and serum using 96-well plates. MethodsX, Volume 7, 2020, 101111. https://www.sciencedirect.com/science/article/pii/S2215016120303319
  4. Gallen, C. et al. Temporal trends of perfluoroalkyl substances in an Australian wastewater treatment plant: A ten-year retrospective investigation. Science of The Total Environment, Volume 804, 2022, 150211. https://www.sciencedirect.com/science/article/abs/pii/S0048969721052888
  5. Winchell, L.J. et al. Analyses of per- and polyfluoroalkyl substances (PFAS) through the urban water cycle: Toward achieving an integrated analytical workflow across aqueous, solid, and gaseous matrices in water and wastewater treatment. Science of The Total Environment, Volume 774, 2021, 145257. https://www.sciencedirect.com/science/article/pii/S0048969721003235

 

 

RUO-MKT-18-14771-A

Questions and answers to help improve your mycotoxin analysis

During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Posted by

Craig has worked in the mass spectrometry industry for over 20 years and has been with SCIEX since 2016. As a senior product application specialist, he works with customers to understand their targeted screening workflows and provide solutions using high-resolution accurate mass spectrometry technologies.

Tags


0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial